Collectively, ISGs as a group are significantly downregulated upon tofacitinib treatment, but the effect is not uniform across all ISGs (Figure 6c), indicating that JAK1/3 inhibition does not reduce all IFN signaling elevated in DS, which could be explained by the fact that the IFN pathways also employ JAK2 for signal transduction (Schwartz et al., 2016; Schwartz et al., 2017). This evidence concerns the gene JAK1 and Dravet syndrome.